Shifting role of cytoreductive nephrectomy according to type of systemic therapy: A nationwide cohort study
CONCLUSION: About a quarter patients with mRCC from a nationwide database were treated with CN and ST. CN was beneficial in specific patients with mRCC. Patient selection is crucial for obtaining the benefits of CN.PMID:35450758 | DOI:10.1016/j.asjsur.2022.04.008 (Source: Asian Journal of Surgery)
Source: Asian Journal of Surgery - April 22, 2022 Category: Surgery Authors: Se Young Choi Moon Soo Ha Jeong Woo Lee Jae Hwan Kim Jung Hoon Kim Byung Hoon Chi Jin Wook Kim In Ho Chang Tae-Hyoung Kim Soon Chul Myung Source Type: research
Interleukin-35 Mitigates ox-LDL-Induced Proatherogenic Effects via Modulating miRNAs Associated with Coronary Artery Disease (CAD)
CONCLUSION: Our observations uncover the novel role of IL-35 as an epigenetic modifier as it influences the expression level of miRNAs implicated in the pathogenesis of atherosclerosis. Thus, IL-35 cytokine therapy-mediated miRNA targeting could be an effective therapeutic strategy against the development of early atheromas in asymptomatic high-risk CAD patients.PMID:35435604 | DOI:10.1007/s10557-022-07335-x (Source: Atherosclerosis)
Source: Atherosclerosis - April 18, 2022 Category: Cardiology Authors: Shipra Bhansali Amit Kumar Yadav Chetan Bakshi Veena Dhawan Source Type: research
Interleukin-35 Mitigates ox-LDL-Induced Proatherogenic Effects via Modulating miRNAs Associated with Coronary Artery Disease (CAD)
ConclusionOur observations uncover the novel role of IL-35 as an epigenetic modifier as it influences the expression level of miRNAs implicated in the pathogenesis of atherosclerosis. Thus, IL-35 cytokine therapy –mediated miRNA targeting could be an effective therapeutic strategy against the development of early atheromas in asymptomatic high-risk CAD patients. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 18, 2022 Category: Cardiology Source Type: research
Favipiravir for the treatment of COVID-19 pneumonia: Can we predict the response to treatment?
Conclusions: Patients with non-severe pneumonia at admission and whose fever resolved within two days of treatment are more likely to improve with favipiravir. (Source: The Journal of Infection in Developing Countries)
Source: The Journal of Infection in Developing Countries - March 30, 2022 Category: Infectious Diseases Source Type: research
Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment
J Immunol Res. 2022 Mar 18;2022:8052212. doi: 10.1155/2022/8052212. eCollection 2022.ABSTRACTWith the huge therapeutic potential, cancer immunotherapy is expected to become the mainstream of cancer treatment. In the current field of cancer immunotherapy, there are mainly five types. Immune checkpoint blockade therapy is one of the most promising directions. Adoptive cell therapy is an important component of cancer immunotherapy. The therapy with the cancer vaccine is promising cancer immunotherapy capable of cancer prevention. Cytokine therapy is one of the pillars of cancer immunotherapy. Oncolytic immunotherapy is a prom...
Source: Journal of Immunology Research - March 28, 2022 Category: Allergy & Immunology Authors: Ling Yang Qian Ning Sheng-Song Tang Source Type: research
The Role of Tumor Necrosis Factor Associated Factors (TRAFs) in Vascular Inflammation and Atherosclerosis
Front Cardiovasc Med. 2022 Feb 17;9:826630. doi: 10.3389/fcvm.2022.826630. eCollection 2022.ABSTRACTTNF receptor associated factors (TRAFs) represent a family of cytoplasmic signaling adaptor proteins that regulate, bundle, and transduce inflammatory signals downstream of TNF- (TNF-Rs), interleukin (IL)-1-, Toll-like- (TLRs), and IL-17 receptors. TRAFs play a pivotal role in regulating cell survival and immune cell function and are fundamental regulators of acute and chronic inflammation. Lately, the inhibition of inflammation by anti-cytokine therapy has emerged as novel treatment strategy in patients with atherosclerosis...
Source: Atherosclerosis - March 7, 2022 Category: Cardiology Authors: Mark Colin Gissler Peter Stachon Dennis Wolf Timoteo Marchini Source Type: research
The Role of Tumor Necrosis Factor Associated Factors (TRAFs) in Vascular Inflammation and Atherosclerosis
Front Cardiovasc Med. 2022 Feb 17;9:826630. doi: 10.3389/fcvm.2022.826630. eCollection 2022.ABSTRACTTNF receptor associated factors (TRAFs) represent a family of cytoplasmic signaling adaptor proteins that regulate, bundle, and transduce inflammatory signals downstream of TNF- (TNF-Rs), interleukin (IL)-1-, Toll-like- (TLRs), and IL-17 receptors. TRAFs play a pivotal role in regulating cell survival and immune cell function and are fundamental regulators of acute and chronic inflammation. Lately, the inhibition of inflammation by anti-cytokine therapy has emerged as novel treatment strategy in patients with atherosclerosis...
Source: Atherosclerosis - March 7, 2022 Category: Cardiology Authors: Mark Colin Gissler Peter Stachon Dennis Wolf Timoteo Marchini Source Type: research
Development of Delivery Systems for Local Administration of Cytokines/Cytokine Gene-Directed Therapeutics: Modern Oncologic Implications
AbstractPurpose of ReviewIn this review, we discuss modern cytokine delivery systems in oncologic care, focusing on modalities being developed in the clinical trials or currently in use. These include pegylation, immune-cytokine drug conjugates, cytokine-expressing plasmid nanoparticles, nonviral cytokine nanoparticles, viral systems, and AcTakines.Recent FindingsCytokine therapy has the potential to contribute to cancer treatment options by modulating the immune system towards an improved antitumor response and has shown promise both independently and in combination with other immunotherapy agents. Despite promising preli...
Source: Current Oncology Reports - February 10, 2022 Category: Cancer & Oncology Source Type: research
Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment
Though single tumor immunotherapy and radiotherapy have significantly improved the survival rate of tumor patients, there are certain limitations in overcoming tumor metastasis, recurrence, and reducing side effects. Therefore, it is urgent to explore new tumor treatment methods. The new combination of radiotherapy and immunotherapy shows promise in improving therapeutic efficacy and reducing recurrence by enhancing the ability of the immune system to recognize and eradicate tumor cells, to overcome tumor immune tolerance mechanisms. Nanomaterials, as new drug-delivery-system materials of the 21st century, can maintain the...
Source: Frontiers in Oncology - February 7, 2022 Category: Cancer & Oncology Source Type: research
Anti-cytokine therapy and small molecule agents for the treatment of inflammatory bowel disease
Eur Cytokine Netw. 2021 Dec 1;32(4):73-82. doi: 10.1684/ecn.2021.0472.ABSTRACTInflammatory bowel disease (IBD), including Crohn disease and ulcerative colitis, with multifactorial etiologies has led to a global health-associated burden in many countries. Substantial efforts are devoted to understand the pathogenesis, behavioral and environmental triggers, which may be specifically valuable for the treatment of IBD. The specific pathogenesis underlying IBD is as yet incompletely understood. The use of anti-cytokine therapy and small molecule agents targeting the immune system is thought to restore the body's intestinal barr...
Source: European Cytokine Network - February 4, 2022 Category: Molecular Biology Authors: Yuancong Jiang Deqiang Kong Xiaolong Miao Xing Yu Zelai Wu Han Liu Weihua Gong Source Type: research
